Voya Investment Management LLC Takes $1.80 Million Position in AnaptysBio, Inc. $ANAB

Key Points

• Voya Investment Management LLC has acquired 96,972 shares of AnaptysBio, Inc., valued at approximately $1.8 million, which accounts for 0.33% of the company's total shares.
• Analyst ratings for AnaptysBio have recently improved, with multiple firms raising their price targets, including a notable increase by JPMorgan Chase & Co. from $42 to $80.
• AnaptysBio reported $22.26 million in revenue for the last quarter, significantly exceeding analysts’ expectations of $11.55 million, despite an EPS of -$1.34.

Voya Investment Management LLC bought a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 96,972 shares of the biotechnology company's stock, valued at approximately $1,803,000. Voya Investment Management LLC owned approximately 0.33% of AnaptysBio as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Rhumbline Advisers increased its stake in shares of AnaptysBio by 2.7% during the first quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company's stock worth $574,000 after purchasing an additional 826 shares in the last quarter. Woodline Partners LP increased its stake in shares of AnaptysBio by 63.1% during the first quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company's stock worth $14,705,000 after purchasing an additional 305,950 shares in the last quarter. Exome Asset Management LLC purchased a new stake in shares of AnaptysBio during the first quarter worth about $2,168,000. Granahan Investment Management LLC increased its stake in shares of AnaptysBio by 38.1% during the first quarter. Granahan Investment Management LLC now owns 146,491 shares of the biotechnology company's stock worth $2,723,000 after purchasing an additional 40,412 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in shares of AnaptysBio by 153.3% during the first quarter. AQR Capital Management LLC now owns 30,011 shares of the biotechnology company's stock worth $558,000 after purchasing an additional 18,165 shares in the last quarter.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Wedbush reaffirmed an "outperform" rating and set a $45.00 price objective on shares of AnaptysBio in a research note on Tuesday, September 16th. HC Wainwright raised shares of AnaptysBio from a "neutral" rating to a "buy" rating and upped their price objective for the company from $22.00 to $38.00 in a research note on Wednesday, June 4th. Guggenheim reaffirmed a "buy" rating and set a $90.00 price objective (up previously from $54.00) on shares of AnaptysBio in a research note on Wednesday, May 28th. JPMorgan Chase & Co. upped their price objective on shares of AnaptysBio from $42.00 to $80.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Finally, UBS Group reaffirmed a "neutral" rating and set a $20.00 price objective (up previously from $18.00) on shares of AnaptysBio in a research note on Tuesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, AnaptysBio currently has a consensus rating of "Moderate Buy" and a consensus price target of $46.13.

Insider Transactions at AnaptysBio

In other AnaptysBio news, Director Hollings Renton sold 20,925 shares of the stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $23.57, for a total transaction of $493,202.25. Following the sale, the director directly owned 4,965 shares in the company, valued at $117,025.05. This represents a 80.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 33.50% of the stock is currently owned by company insiders.

AnaptysBio Stock Performance

Shares of NASDAQ:ANAB traded up $0.56 during mid-day trading on Monday, reaching $21.40. 457,351 shares of the company were exchanged, compared to its average volume of 523,960. The firm's 50-day simple moving average is $22.47 and its 200 day simple moving average is $21.31. AnaptysBio, Inc. has a 1 year low of $12.21 and a 1 year high of $38.67.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share for the quarter, topping analysts' consensus estimates of ($1.50) by $0.16. The firm had revenue of $22.26 million during the quarter, compared to analysts' expectations of $11.55 million. AnaptysBio had a negative net margin of 107.66% and a negative return on equity of 366.98%. Equities research analysts forecast that AnaptysBio, Inc. will post -6.08 EPS for the current year.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.